Sensipar en es it fr

Sensipar Brand names, Sensipar Analogs

Sensipar Brand Names Mixture

  • No information avaliable

Sensipar Chemical_Formula


Sensipar RX_link

Sensipar fda sheet

Sensipar FDA

Sensipar msds (material safety sheet)

Sensipar Synthesis Reference

No information avaliable

Sensipar Molecular Weight

357.412 g/mol

Sensipar Melting Point

No information avaliable

Sensipar H2O Solubility

Slightly soluble (in HCl salt form)

Sensipar State


Sensipar LogP


Sensipar Dosage Forms

Tablets (light-green, film-coated, oval-shaped tablets for oral administration in strengths of 30 mg, 60 mg, and 90 mg)

Sensipar Indication

For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Sensipar Pharmacology

Cinacalcet is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues). Secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) is a progressive disease, associated with increases in parathyroid hormone (PTH) levels and derangements in calcium and phosphorus metabolism. Increased PTH stimulates osteoclastic activity resulting in cortical bone resorption and marrow fibrosis. The goals of treatment of secondary hyperparathyroidism are to lower levels of PTH, calcium, and phosphorus in the blood, in order to prevent progressive bone disease and the systemic consequences of disordered mineral metabolism. In CKD patients on dialysis with uncontrolled secondary HPT, reductions in PTH are associated with a favorable impact on bone-specific alkaline phosphatase (BALP), bone turnover and bone fibrosis. Cinacalcet reduces calcium levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium.

Sensipar Absorption

Rapidly absorbed following oral administration.

Sensipar side effects and Toxicity

Doses titrated up to 300 mg once daily have been safely administered to patients on dialysis. Overdosage of cinacalcet may lead to hypocalcemia.

Sensipar Patient Information

No information avaliable

Sensipar Organisms Affected

Humans and other mammals